Illumina (ILMN) Income from Continuing Operations (2009 - 2026)
Illumina's (ILMN) quarterly Income from Continuing Operations came in at $207.0 million in Q2 2026, down 11.91% on a YoY basis from $235.0 million in Q2 2025, and up 54.48% quarter-over-quarter from $134.0 million in Q1 2026.
Analysis
Illumina (ILMN) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Illumina (ILMN) has reported Income from Continuing Operations for 18 consecutive years, with $207.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations fell 11.91% year-over-year to $207.0 million; the trailing twelve-month figure through Jun 2026 stood at $825.0 million (down 34.42% YoY), and the FY2025 full-year result was $850.0 million, up 169.5% from the prior year.
- Income from Continuing Operations rose to $207.0 million in Q2 2026 per ILMN's latest filing, from $134.0 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $705.0 million in Q3 2024 and bottomed at -$5.1 billion in Q1 2023.
- Historically, Income from Continuing Operations has averaged -$583.9 million across 5 years, with a median of $44.5 million in 2022.
- The widest YoY moves for Income from Continuing Operations: up 206.86% in 2024, down 4300.0% in 2024.
- Over 5 years, Income from Continuing Operations stood at -$3.8 billion in 2022, then soared by 95.41% to -$175.0 million in 2023, then soared by 206.86% to $187.0 million in 2024, then surged by 78.61% to $334.0 million in 2025, then slumped by 38.02% to $207.0 million in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered $207.0 million, $134.0 million, and $334.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | 362.00 Mn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | 207.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | 53.48 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | 54.62 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | 371.40 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | 5.01 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | -17.93 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | -65.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 28, 2026 | 207.00 Mn |
| Mar 29, 2026 | 134.00 Mn |
| Dec 28, 2025 | 334.00 Mn |
| Sep 28, 2025 | 150.00 Mn |
| Jun 29, 2025 | 235.00 Mn |
| Mar 30, 2025 | 131.00 Mn |
| Dec 29, 2024 | 187.00 Mn |
| Sep 29, 2024 | 705.00 Mn |
| Jun 30, 2024 | -1.99 Bn |
| Mar 31, 2024 | -126.00 Mn |
| Dec 31, 2023 | -175.00 Mn |
| Oct 1, 2023 | -754.00 Mn |
| Jul 2, 2023 | -234.00 Mn |
| Apr 2, 2023 | 3.00 Mn |
| Jan 1, 2023 | -5.05 Bn |
| Oct 2, 2022 | -3.82 Bn |
| Jul 3, 2022 | -535.00 Mn |
| Apr 3, 2022 | 86.00 Mn |
| Oct 3, 2021 | 317.00 Mn |
| Jul 4, 2021 | 185.00 Mn |